ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Alexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data At The American Headache Society Annual Scientific Meeting
Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present
results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for
the treatment of migraine headache at the 50th Annual Scientific Meeting of
the American Headache Society, which being held at the Marriott Boston
Copley Place in Boston, MA. The oral platform abstract presentation,
"Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients
Having an Acute Migraine Attack", is scheduled for Friday, June 27, 2008 at
10:55 a.m. Eastern Time, and will be presented in University Hall. AZ-104
is a lower dose version of AZ-004, which is in Phase 3 clinical development
for the treatment of acute agitation in patients with schizophrenia or
bipolar disorder.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company
focused on the development and commercialization of novel, proprietary
products for the treatment of acute and intermittent conditions. The
Company's technology, the Staccato system, vaporizes unformulated drug to
form a condensation aerosol that allows rapid systemic drug delivery
through deep lung inhalation. The drug is quickly absorbed through the
lungs into the bloodstream, providing speed of therapeutic onset that is
comparable to intravenous administration, but with greater ease, patient
comfort and convenience.
Alexza has six product candidates in clinical development. Alexza's
lead program, AZ-004 (Staccato loxapine) for the treatment of acute
agitation in schizophrenic or bipolar disorder patients, is in Phase 3
testing and has completed the enrollment of its first Phase 3 clinical
trial. AZ-001 (Staccato prochlorperazine) for the acute treatment of
migraine headaches has completed Phase 2 testing. AZ-104 (Staccato
loxapine) for the acute treatment of migraine headaches and AZ-002
(Staccato alprazolam) for the acute treatment of panic attacks associated
with panic disorder are in Phase 2 testing. Product candidates in Phase 1
testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough
pain, which is partnered with Endo Pharmaceuticals in North America, and
AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information,
including this and past press releases from Alexza is available online at
http://www.alexza.com.
Safe Harbor Statement
The anticipated scientific presentation will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of
1995, and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those inherent in
the process of developing and commercializing drugs. The Company's
forward-looking statements also involve assumptions that, if they prove
incorrect, would cause its results to differ materially from those
expressed or implied by such forward- looking statements. These and other
risks concerning Alexza's business are described in additional detail in
the Company's Annual Report on Form 10-K for the year ended December 31,
2007, and the Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements contained in
the poster presentation are made as of their date of presentation, and the
Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Alexza Pharmaceuticals, Inc.
http://www.alexza.com
Alexza Pharmaceuticals sã prezinte AZ-104 date clinice de fazã 2a La The American Cefalee Societatea anual ºtiinþific pentru intalniri - Alexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data At The American Headache Society Annual Scientific Meeting - articole medicale engleza - startsanatate